GLP's Cardiovascular Outcomes: What the Latest Data Shows
Cardiovascular outcomes data for GLP's receptor agonists has been a major focus of recent research. Here is what the evidence shows and what it means for prescribers.
GLP-1 Cardiovascular Outcomes: What the Latest Data Shows
The GLP-1 receptor agonist class has produced some of the most compelling cardiovascular outcomes data in recent pharmaceutical history. For prescribers offering compounded GLP-1 programs, understanding this evidence base strengthens your clinical rationale and helps you counsel patients about the full scope of benefits.
The SELECT Trial: Semaglutide and Cardiovascular Risk
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark study published in The New England Journal of Medicine in 2023. Key findings:
Study design: 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Randomized to semaglutide 2.4 mg weekly (Wegovy dose) vs. placebo.
Primary outcome: Major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Results: Semaglutide reduced MACE by 20% compared to placebo (HR 0.80, 95% CI 0.72–0.90). This was statistically significant and clinically meaningful.
Weight loss: Participants on semaglutide lost an average of 9.4% of body weight vs. 0.9% in the placebo group.
Significance: This was the first trial to demonstrate cardiovascular risk reduction with a GLP-1 agonist in people without diabetes who were overweight or obese. It established semaglutide as a cardiovascular risk reduction agent, not just a weight loss drug.
SURMOUNT-MMO: Tirzepatide Cardiovascular Outcomes
Following the SELECT trial, Eli Lilly launched the SURMOUNT-MMO trial to evaluate tirzepatide's cardiovascular outcomes in a similar population. Results are expected in 2026–2027.
Preliminary data and mechanistic studies suggest tirzepatide may produce cardiovascular benefits comparable to or exceeding those of semaglutide, given its dual GLP-1/GIP mechanism and superior weight loss outcomes.
TRIUMPH-3: Retatrutide Cardiovascular Outcomes
Eli Lilly's Phase 3 program for retatrutide includes a dedicated cardiovascular outcomes trial (TRIUMPH-3). Given retatrutide's triple mechanism and superior weight loss in Phase 2, there is significant interest in whether it will produce even greater cardiovascular risk reduction.
Results are not yet available, but the trial design mirrors SELECT and SURMOUNT-MMO.
Mechanisms of Cardiovascular Benefit
The cardiovascular benefits of GLP-1 agonists appear to be mediated through multiple mechanisms:
Weight loss: Obesity is a major cardiovascular risk factor. Weight loss reduces blood pressure, improves lipid profiles, and reduces inflammatory markers.
Direct cardiac effects: GLP-1 receptors are expressed in cardiac tissue. GLP-1 agonists may have direct cardioprotective effects independent of weight loss.
Anti-inflammatory effects: GLP-1 agonists reduce systemic inflammation, which is a key driver of atherosclerosis.
Blood pressure reduction: GLP-1 agonists consistently reduce systolic blood pressure by 3–5 mmHg on average.
Lipid effects: Improvements in triglycerides and HDL cholesterol are commonly observed.
What This Means for Prescribers
Expanded Indication Rationale
The cardiovascular outcomes data expands the clinical rationale for GLP-1 prescribing beyond weight loss. Patients with cardiovascular risk factors — hypertension, dyslipidemia, prior cardiovascular events — have a particularly strong evidence base for GLP-1 therapy.
Patient Counseling
Patients often think of GLP-1 therapy purely in terms of weight loss. Counseling them about the cardiovascular benefits can improve adherence and help them understand the full value of the therapy.
Documentation
Documenting the cardiovascular risk factors that support GLP-1 prescribing strengthens the clinical rationale in the medical record — important for both clinical quality and regulatory compliance.
Compounded vs. Branded
The cardiovascular outcomes data was generated with branded semaglutide (Wegovy dose) and branded tirzepatide. Compounded preparations use the same active ingredients, but the outcomes data was not generated with compounded products specifically. Prescribers should be transparent with patients about this distinction.
The Bottom Line
The cardiovascular outcomes data for GLP-1 agonists is among the strongest in modern obesity medicine. For practices offering compounded GLP-1 programs, this evidence base provides a compelling clinical foundation — and a powerful patient education tool.
This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should review current literature and use clinical judgment.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
